Arenberg Sciene Park, Leuven
Dynamic cluster in Leuven
High-tech and innovation in the knowledge region Leuven
Arenberg Science Park is located in Leuven and is part of the Brussels Metropolitan Area. This is the area between Antwerp, Ghent and Leuven and is also known as the Flemish Diamond. This area is economically comparable to the Randstad in the Netherlands and the Rhine-Ruhr area in Northern Germany.
Kurt De Nil M: +32 494 624 279 E: k.nil@kadans.com
European capital of innovation
Leuven was the European Capital of Innovation in 2020. Four major technology domains have emerged in the Leuven region in recent years, creating dynamic clusters in the areas of life sciences, nanotechnology, mechatronics & smart systems. The award recognises Leuven’s outstanding innovation concepts, as well as processes and governance models that create a framework that brings ideas to life.
KU Leuven
The Katholieke Universiteit Leuven (KUL) consistently scores high in the rankings of the best and most innovative universities in the world. KUL is a university with a wide range of faculties, with a particular focus on Biomedical Sciences, Humanities & Social Sciences. The Faculty of Biomedical Sciences is prestigious and widely known for their innovations.
KU Leuven currently has 60,600 students. 20% of the students come from abroad, underlining its international character. The university’s growth facilitates R&D (spin offs) and entrepreneurship.
Spaces on Arenberg Science Park
In the area
Latest news from the Kadans Community
Genmab and Synaffix Enter into License Agreement for ADC Technology
COPENHAGEN, Denmark and AMSTERDAM, Netherlands; 4 January, 2022 — Genmab A/S (Nasdaq: GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies. Genmab is granted exclusive research rights
Khondrion completes enrollment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders
NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announced that the last patient has been dosed with sonlicromanol in the
Briskr workshops in januari en februari
Every month, Briskr organizes different workshops. In December and January, the following workshops are planned. Register now and let yourself be inspired. How to build a successful team? Date: January 24, 2022 Time: 14:00 -
I want more
information